Suppr超能文献

地高辛的临床药代动力学

Clinical pharmacokinetics of digoxin.

作者信息

Iisalo E

出版信息

Clin Pharmacokinet. 1977 Jan-Feb;2(1):1-16. doi: 10.2165/00003088-197702010-00001.

Abstract

About 70 to 80% of an oral dose of digoxin is absorbed, mainly in the proximal part of the small intestine. The degree of binding to serum albumin is 20 to 30%. Digoxin is extensively distributed in the tissues, as reflected by the large volume of distribution. High concentrations are found in the heart and kidneys, but the skeletal muscles form the largest digoxin storage. The half-life of elimination in healthy persons varies between 26 and 45 hours. The main route of elimination is renal excretion of digoxin, which is closely correlated with the glomerular filtration rate. In addition, some tubular secretion and perhaps tubular reabsorption occurs. Nearly all of the digoxin in the urine is excreted unchanged, with a small part as active metabolites. The clinical significance of dihydrodigoxin as a metabolite remains to be resolved. About 25 to 28% of digoxin is eliminated by nonrenal routes. Biliary excretion may rise up to 30% of a given dose, but the enterohepatic cycle seems to be of minor importance. The pharmacodynamic effects of digoxin, including toxic symptoms, are correlated with the uptake of digoxin in the heart after a single dose and with the steady state serum digoxin concentration during maintenance therapy. Impaired kidney function is the most important condition with an influence on the pharmacokinetics of digoxin. In addition to the renal clearance of creatinine, the biovailability of the digoxin formulation used, the volume of distribution, the amount of extrarenal clearance, body weight and serum albumin concentration, are other factors which may modify the serum level of digoxin. Certain drug interactions may also occur during the absorptive phase. Exact prediction of serum digoxin concentrations by various dosage calculations has not succeeded. Since many factors may influence the sensitivity of the myocardium to digoxin, measurement of serum digoxin levels in only one, but a useful criterion, when making clinical decisions about adjustment of digoxin dosage.

摘要

口服地高辛剂量的约70%至80%被吸收,主要在小肠近端。与血清白蛋白的结合程度为20%至30%。地高辛广泛分布于组织中,分布容积大即反映了这一点。心脏和肾脏中浓度较高,但骨骼肌是地高辛最大的储存部位。健康人的消除半衰期在26至45小时之间。消除的主要途径是地高辛经肾脏排泄,这与肾小球滤过率密切相关。此外,还存在一些肾小管分泌,可能还有肾小管重吸收。尿液中几乎所有的地高辛都是以原形排泄,只有一小部分是活性代谢物。二氢地高辛作为代谢物的临床意义尚待解决。约25%至28%的地高辛通过非肾脏途径消除。胆汁排泄量可能高达给定剂量的30%,但肠肝循环似乎不太重要。地高辛的药效学作用,包括毒性症状,与单次给药后心脏对地高辛的摄取以及维持治疗期间的稳态血清地高辛浓度相关。肾功能受损是对地高辛药代动力学有影响的最重要情况。除了肌酐的肾清除率外,所用的地高辛制剂的生物利用度、分布容积、肾外清除量、体重和血清白蛋白浓度等其他因素也可能改变地高辛的血清水平。在吸收阶段也可能发生某些药物相互作用。通过各种剂量计算精确预测血清地高辛浓度尚未成功。由于许多因素可能影响心肌对地高辛的敏感性,在做出关于调整地高辛剂量的临床决策时,仅测定血清地高辛水平是一个有用但不唯一的标准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验